Sažetak
Background: This study aims at investigating the relationship HBV RNA level and pregnancy outcomes among hepatitis B carriers.
Methods: A total of 562 pregnant women who attended the Affiliated Hospital of Guizhou Medical University (Guizhou, China) from June 2020 to June 2023 were collected, 203 HBV carriers was included in this study. Then we recorded general data and pregnancy outcomes, the levels of HBV DNA, HBV RNA and HBeAg status in HBV carrier were detected. Pregnancy outcomes including intrahepatic cholestasis of pregnancy (ICP), gestational hypertension (GH), pre-eclampsia, gestational diabetes mellitus (GDM), preterm prelabour rupture of membranes (PPROM), mode of delivery , preterm birth, low birth weight (LBW) and macrosomia.
Results: 562 pregnancies were analyzed, 203(36.12%) were infected with hepatitis B virus. Compared with HBsAg negative, HBsAg positive pregnant women had a higher risk of ICP. No statistically significant differences were found in the rates of GDM, GH, pre-eclampsia, PPROM, preterm birth, LBW, macrosomia and mode of delivery among women with the two groups. The analysis of risk factors of ICP showed that maternal HBV RNA level (OR = 3.814, 95% CI: 2.036~7.142, P< 0.001) was an important risk factor for ICP in HBsAg positive pregnant women. The receiver operating characteristics (ROC) curve revealed that the areas under the HBV RNA was 0.8652(95% confidence interval 0.7636~0.9669, P< 0.001).
Conclusion: HBV RNA level pose significant negative impact to the pregnancy outcomes. It can be used as indicators to guide the prevention of ICP and improve maternal outcomes.
Ključne reči
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.